National Academies Press: OpenBook
« Previous: Appendix C: Statement of Task
Suggested Citation:"Appendix D: Registered Attendees." Institute of Medicine. 2012. Genome-Based Therapeutics: Targeted Drug Discovery and Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13436.
×

Appendix D

Registered Attendees

Brian Abbott

AstraZeneca Pharmaceuticals

Nathan Adams

Defense Threat Reduction Agency, Department of Defense

Margaret Anderson

FasterCures

Euan Ashley

Stanford University

Christopher Austin

National Center for Advancing Translational Sciences, National Institutes of Health

Sarah Beachy

National Cancer Institute, National Institutes of Health

Judith Benkendorf

American College of Medical Genetics

Anahita Bhathena

Abbott Laboratories

Paul Billings

Life Technologies

Bruce Blumberg

Kaiser Permanante

Denise Bonds

National Heart, Lung, and Blood Institute, National Institutes of Health

Ann Bonham

Association of American Medical Colleges

Kristopher Bough

National Institute on Drug Abuse, National Institutes of Health

Joann Boughman

American Society of Human Genetics

Suggested Citation:"Appendix D: Registered Attendees." Institute of Medicine. 2012. Genome-Based Therapeutics: Targeted Drug Discovery and Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13436.
×

Khaled Bouri

U.S. Food and Drug Administration

Linda Brady

National Institutes of Health

Apryl Brown

Wayne County Community College District

Wylie Burke

University of Washington

Walter Capone

Multiple Myeloma Research Foundation

Carolyn Carroll

STAT TECH Inc.

Christine Carter

Society for Women’s Health Research

C. Thomas Caskey

Baylor College of Medicine

Chia-Chien Chiang

Human Genome Sciences, Inc.

Lisa Chong

Science

Melina Cimler

Illumina

Sara Copeland

Health Resources and Services Administration

Sean David

Stanford University School of Medicine

Nicholas Davies

PricewaterhouseCoopers LLP

Silvana Dean

U.S. Food and Drug Administration

Jamie Driscoll

National Institute of Mental Health, National Institutes of Health

Rade Drmanac

Complete Genomics

Deborah Dunsire

Millennium: The Takeda Oncology Company

Victor Dzau

Duke University Health System

Peggy Eastman

Oncology Times

Amy Efantis

Boehringer Ingelheim Pharmaceuticals, Inc.

Raith Erickson

Complete Genomics

Cynthia Ewel

Medco Research Institute

W. Gregory Feero

National Human Genome Research Institute, National Institutes of Health

Mandy Field

Children’s National Medical Center

Gary Filerman

Atlas Health Foundation

Suggested Citation:"Appendix D: Registered Attendees." Institute of Medicine. 2012. Genome-Based Therapeutics: Targeted Drug Discovery and Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13436.
×

Ross Filice

U.S. Food and Drug Administration

Kelly Filipski

National Cancer Institute

Andrew Fish

AdvaMedDx

Garret FitzGerald

Perelman School of Medicine, University of Pennsylvania

Cathy Fomous

National Institutes of Health

Richard Forshee

U.S. Food and Drug Administration

Jane Fridlyand

Genentech

Felix Frueh

Medco Research Institute

Dean Gaalaas

EdgeBio

Ron Galloway

Method Content LLC

John Gardenier

Independent

Turkan Gardenier

Pragmatica Corporation

Fathia Gibril

U.S. Food and Drug Administration

Geoffrey Ginsburg

Duke University

Andrea Giuffrida

National Institutes of Health

Evan Hadley

National Institute on Aging, National Institutes of Health

Margaret Hamburg

U.S. Food and Drug Administration

Steffan Ho

Pfizer Inc.

Carolyn Hoban

Multiple Myeloma Research Foundation

Damon Hostin

Complete Genomics

Florence Houn

Celgene

Kathy Hudson

National Center for Advancing Translational Sciences, National Institutes of Health

Sheikh Mohammed Shariful Islam

International Centre for Diarrhoeal Disease Research, Bangladesh

Jean Jenkins

National Human Genome Research Institute, National Institutes of Health

Justin Johnson

EdgeBio

Carolyn Jones

Biogen Idec

Suggested Citation:"Appendix D: Registered Attendees." Institute of Medicine. 2012. Genome-Based Therapeutics: Targeted Drug Discovery and Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13436.
×

Thea Kalebic

Millennium: The Takeda Oncology Company

Francis Kalush

Center for Devices and Radiological Health, U.S. Food and Drug Administration

Sharon Kardia

University of Michigan

Nobuko Katagiri

U.S. Food and Drug Administration

John Kehne

Translational Neuropharmacology Consulting LLC

John Kenten

Mesoscale Diagnostics

Mohamed Khan

British Columbia Cancer Agency

Muin Khoury

Centers for Disease Control and Prevention

Chava Kimchi-Sarfaty

U.S. Food and Drug Administration

Roger Klein

Esther & Hyman Rapport Philanthropic Trust

Hon-Sum Ko

U.S. Food and Drug Administration

Susan Koester

National Institute of Mental Health, National Institutes of Health

Kathy Kopnisky

National Institutes of Health

Courtney Lang

Pepperdine University

Thomas Lehner

National Institute of Mental Health, National Institutes of Health

Debra Leonard

Weill Cornell Medical Center

Emily Levy

Synergy Partners

Michelle Lewis

Johns Hopkins University

Len Lichtenfeld

American Cancer Society

Michele Lloyd-Puryear

Office of Rare Diseases Research, National Institutes of Health

Laurence McCarthy

Scientific Technologies & Solutions, LLC

Michael McCaughan

RPM Report

Robert McCormack

Veridex, LLC

Kathryn McLaughlin

Health Resources and Services Administration

Melodi McNeil

Abbott Laboratories

Suggested Citation:"Appendix D: Registered Attendees." Institute of Medicine. 2012. Genome-Based Therapeutics: Targeted Drug Discovery and Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13436.
×

Amy Miller

Personalized Medicine Coalition

Helen Moore

National Cancer Institute, National Institutes of Health

Richard Morris

National Institutes of Health

Peter Mueller

Vertex Pharmaceuticals

Arnulfo Muralles

American Association for the Advancement of Science

Laura Nisenbaum

Eli Lilly and Company

Lolita O’Donnell

Defense Centers of Excellence for Psychological Health and Traumatic Brain Injury

Steve Olson

Independent Consultant

Michael Pacanowski

U.S. Food and Drug Administration

Gustavo Palacios

Center for Genomic Sciences

Gary Palmer

Foundation Medicine

Lydia Pan

Pfizer Inc.

Gillian Parrish

FasterCures

Praveen Pendyala

Center for Studying Health System Change

Michelle Penny

Eli Lilly and Company

Margaret Piper

BlueCross BlueShield Association

Laura Povlich

U.S. House of Representatives

Aidan Power

Pfizer Inc.

Arundeep Pradhan

Oregon Health & Science University

Victoria Pratt

Quest Diagnostics

Ronald Przygodzki

Department of Veterans Affairs

Drena Reaves-Bey

Parenting Before Conception

Cynthia Reilly

American Society of Health-System Pharmacists

Jon Retzlaff

American Association for Cancer Research

Max Robinowitz

U.S. Food and Drug Administration

Bob Roehr

British Medical Journal

Suggested Citation:"Appendix D: Registered Attendees." Institute of Medicine. 2012. Genome-Based Therapeutics: Targeted Drug Discovery and Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13436.
×

Allen Roses

Duke University

Deborah Runkle

American Association for the Advancement of Science

Lisa Schlager

Facing Our Risk of Cancer Empowerment

Derek Scholes

National Human Genome Research Institute, National Institutes of Health

Amber Scholz

President’s Council of Advisors on Science and Technology

Joan Scott

National Coalition for Health Professional Education in Genetics

Sam Shekar

Northrop Grumman

Vijaya Simhadri

Center for Biologics Evaluation and Research, U.S. Food and Drug Administration

Tania Simoncelli

U.S. Food and Drug Administration

Dee Simons

Biogen Idec

James Sorace

U.S. Department of Health and Human Services

Ansalan Stewart

U.S. Department of Health and Human Services

Carol Stinson

AstraZeneca Pharmaceuticals

Katherine Johansen Taber

American Medical Association

Zivana Tezak

U.S. Food and Drug Administration

Barry Thompson

American College of Medical Genetics

Javier Torres-Roca

H. Lee Moffitt Cancer Center

Mark Trusheim

MIT Sloan School of Management

Kenneth Tucker

Tauri Group, Inc.

Simona Volpi

National Human Genome Research Institute, National Institutes of Health

Amelia Warner

Merck

Daniel Wattendorf

Department of the Air Force

Jill Wechsler

Pharmaceutical Executive Magazine

Cole Werble

RPM Report

Suggested Citation:"Appendix D: Registered Attendees." Institute of Medicine. 2012. Genome-Based Therapeutics: Targeted Drug Discovery and Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13436.
×

Catherine Wicklund

Northwestern University

Erin Wilhelm

Georgetown University

Hui-Hsing Wong

U.S. Department of Health and Human Services

Suggested Citation:"Appendix D: Registered Attendees." Institute of Medicine. 2012. Genome-Based Therapeutics: Targeted Drug Discovery and Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13436.
×

This page intentionally left blank.

Suggested Citation:"Appendix D: Registered Attendees." Institute of Medicine. 2012. Genome-Based Therapeutics: Targeted Drug Discovery and Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13436.
×
Page 83
Suggested Citation:"Appendix D: Registered Attendees." Institute of Medicine. 2012. Genome-Based Therapeutics: Targeted Drug Discovery and Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13436.
×
Page 84
Suggested Citation:"Appendix D: Registered Attendees." Institute of Medicine. 2012. Genome-Based Therapeutics: Targeted Drug Discovery and Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13436.
×
Page 85
Suggested Citation:"Appendix D: Registered Attendees." Institute of Medicine. 2012. Genome-Based Therapeutics: Targeted Drug Discovery and Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13436.
×
Page 86
Suggested Citation:"Appendix D: Registered Attendees." Institute of Medicine. 2012. Genome-Based Therapeutics: Targeted Drug Discovery and Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13436.
×
Page 87
Suggested Citation:"Appendix D: Registered Attendees." Institute of Medicine. 2012. Genome-Based Therapeutics: Targeted Drug Discovery and Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13436.
×
Page 88
Suggested Citation:"Appendix D: Registered Attendees." Institute of Medicine. 2012. Genome-Based Therapeutics: Targeted Drug Discovery and Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13436.
×
Page 89
Suggested Citation:"Appendix D: Registered Attendees." Institute of Medicine. 2012. Genome-Based Therapeutics: Targeted Drug Discovery and Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13436.
×
Page 90
Genome-Based Therapeutics: Targeted Drug Discovery and Development: Workshop Summary Get This Book
×
Buy Paperback | $36.00 Buy Ebook | $28.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

The number of new drug approvals has remained reasonably steady for the past 50 years at around 20 to 30 per year, while at the same time the total spending on health-related research and development has tripled since 1990. There are many suspected causes for this trend, including increases in regulatory barriers, the rising costs of scientific inquiry, a decrease in research and development efficiency, the downstream effects of patient expirations on investment, and the lack of production models that have successfully incorporated new technology. Regardless, this trajectory is not economically sustainable for the businesses involved, and, in response, many companies are turning toward collaborative models of drug development, whether with other industrial firms, academia, or government. Introducing greater efficiency and knowledge into these new models and aligning incentives among participants may help to reverse the trends highlighted above, while producing more effective drugs in the process.

Genome-Based Therapeutics explains that new technologies have the potential to open up avenues of development and to identify new drug targets to pursue. Specifically, improved validation of gene-disease associations through genomics research has the potential to revolutionize drug production and lower development costs. Genetic information has helped developers by increasing their understanding of the mechanisms of disease as well as individual patients' reactions to their medications. There is a need to identify the success factors for the various models that are being developed, whether they are industry-led, academia-led, or collaborations between the two.

Genome-Based Therapeutics summarizes a workshop that was held on March 21, 2012, titled New Paradigms in Drug Discovery: How Genomic Data Are Being Used to Revolutionize the Drug Discovery and Development Process. At this workshop the goal was to examine the general approaches being used to apply successes achieved so far, and the challenges ahead.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!